Joule's senior management team, directors and advisors represent industry all-stars in the wide-ranging disciplines that are critical to our success; from business strategy and operations to bioscience and engineering. More than a brilliant idea, we've brought together the right people with the "extreme horsepower" to make it reality.
|Noubar Afeyan Chairman and Interim CEO |
Dr. Afeyan is Managing Partner and CEO of Flagship Ventures, a firm that manages over $900 million in early-stage funds across the sectors of Therapeutics, Health Technologies and Sustainability/Clean Technology. A technologist, entrepreneur and venture capitalist, Dr. Afeyan has co-founded and helped build over 25 successful life science and technology start-ups during the past two decades. In addition to Joule, he is a director and co-founder of Flagship portfolio companies Affinnova, BG Medicine, Ensemble Therapeutics, LS9, Midori, Moderna Therapeutics and Pronutria. Previously he was a member of the founding team, director and investor in several successful ventures including Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and Adnexus Therapeutics.
|Paul Snaith President and Chief Operating Officer|
Dr. Snaith joined Joule in 2012 and was later appointed as the company's Chief Business Officer. He previously held multiple roles at Shell over the course of 24 years, most recently serving as Vice President, Downstream Marketing for Shell Global Solutions and as Managing Director of Shell Research, Ltd. During that time his responsibilities included leading the technology strategy for Shell's biofuels business. His prior positions with the company spanned senior leadership roles across multiple Shell businesses and regions, including: Lubricant Product Manager in France; Global Fuels Management roles in the UK; Sales and Marketing Director in Oman; General Manager for Shell's LPG businesses in the Mediterranean, African and South American regions; and Marketing Vice President for the global LPG business. Dr. Snaith holds a PhD and BSc in Biological Sciences from Lancaster University and is a Fellow of the Royal Society of Chemistry.
|Peter Erich President, Joule Fuels|
Mr. Erich oversees Joule's subsidiary responsible for global commercial deployment. He previously spent more than 20 years at Shell in various senior leadership roles around the world. He served as VP, Petroleum Products for Northeast Asia and West Africa; CEO of Global LPG; and as VP, Commercial Business for Europe, Russia and Turkey. Following his work at Shell, Mr. Erich was COO at Nuon, a gas and power company serving more than three million consumers and organizations with 10,000+ employees across the Netherlands, Belgium and Germany. Most recently, he held the role of CEO at Puma Energy International. He holds an MBA from Erasmus University and a VWO from Aloysius College.
|Eric d'Esparbes Senior Vice President and CFO|
Mr. d'Esparbes is an accomplished executive with more than 20 years of experience managing the finance and accounting functions of international energy companies. He most recently served as Vice President of Finance for AEI Services, LLC, which owns and operates more than 50 energy infrastructure companies in 20 countries. He was responsible for optimizing the capital and debt structure of AEI's global portfolio spanning Latin America, Eastern Europe and Asia, and also served as CFO of AEI Asia for three years. Mr. d'Esparbes previously held senior finance roles for Meiya Power Company; an Asia-based power company with 18 investment companies, and Hydro-Quebec International; the international unit of one of the world's largest hydro power companies. He holds a BBA in International Finance from the Universite de Montreal.
|Dan Robertson Chief Scientific Officer|
Dr. Robertson has led the bioscience efforts at Joule since its inception in 2007. Prior to Joule, he served as Director of Enzymology at Diversa Corporation and as Vice President of Biofuels R&D for Verenium, where he led the development of microbial strains for cellulosic ethanol production. In addition to his 14 years of industrial experience, Dr. Robertson also has a 14-year academic background focused on the energetics of membrane transport and photosynthesis. He received his PhD degree in Biochemistry from the University of Pittsburgh.
|Mark Solakian Senior Vice President and General CounselMr. Solakian is a seasoned general counsel and corporate executive with nearly 17 years experience in public and private company matters. He most recently served as Senior Vice President, General Counsel and Corporate Secretary at Helicos BioSciences Corporation, where he was responsible for all legal affairs through the company’s successful IPO, multiple financings, strategic partnerships and corporate restructurings. Prior to Helicos he was Vice President and Chief Corporate Counsel at Affymetrix, Inc., a publicly-traded life sciences company where he oversaw all corporate legal matters. Mr. Solakian was a business law attorney at Goodwin Procter LLP in Boston prior to joining Affymetrix. He holds an AB degree from Harvard University and a JD degree from Boston College Law School.|
|David St. Angelo Senior Vice President, Engineering|
Mr. St. Angelo has a successful track record spanning 20+ years in engineering, including leadership roles in the clean tech and energy industries. He was previously Vice President of Engineering at Skyonic Corporation, where he led the initial conceptualization and development of patented technology for the capture and conversion of carbon into mineral products. Prior to Skyonic, he was Vice President of Large Format Energy Solutions at Valence Technology, Inc., a developer of low-cost energy storage systems using lithium-ion batteries. In that role he led the definition, design, development and commercialization of the division’s large format product line, while also implementing and managing the company’s licensing program. Mr. St. Angelo holds a BS degree in Chemical Engineering from the University of Massachusetts/Amherst and a MS degree in Electrical Engineering from Northeastern University.
|John Ward Senior Vice President, Production|
Mr. Ward oversees Joule's scale-up planning, direction and construction as it advances towards commercial production. He brings substantial experience to the role, having led the design, construction, validation and operations of biopharmaceutical facilities for more than 20 years. Prior to Joule, he served as Vice President of Engineering and Facilities at Biogen Idec, a $4 billion biotechnology company where he held global responsibility for engineering, construction, validation, facilities management, and environmental, health, safety and security, among other functions. He holds an MBA from the Stephen M. Ross School of Business at the University of Michigan, BE and ME degrees in Chemical/Biochemical Engineering from Dartmouth College, and an AB in Physics from Hamilton College.
|Paula A. Cloghessy Vice President, Human Resources|
Ms. Cloghessy has more than 15 years experience building and leading HR programs for large, growing, advancing organizations within the biotech, pharmaceuticals and life sciences industries. Prior to joining Joule, she served as Senior Director of Human Resources for Interleukin Genetics, where she built the human resources function from the ground up, implemented progressive practices to attract and retain top talent, achieve market competitiveness and support organizational development. She previously held senior HR roles at NUCRYST Pharmaceuticals and the Immune Disease Institute (formerly CBR Institute for Biomedical Research), a Harvard Medical School affiliate. Ms. Cloghessy holds a BA in Psychology from the University of Massachusetts and professional SPHR certification in the field of human resources.
|Mike Glacken Vice President, Bioprocessing|
Mr. Glacken's expertise in bioprocess development derives from 15 years of industrial and academic experience. Prior to joining Joule, he served as Site Director for Bioprocess Development at Millennium Pharmaceuticals. He has worked or consulted for biopharmaceutical companies ranging from large to small, including SmithKline Beecham, Bristol-Myers Squibb, Genentech, Genzyme Transgenics, Dow Agrosciences and SemBioSys. He was previously Assistant Professor of Chemical Engineering at Rice University. Mr. Glacken holds a BS degree in Chemical Engineering from the University of Maryland and an ScD degree in Biochemical Engineering from MIT.
|Chang B. Hong Vice President, Intellectual Property Counsel|
Mr. Hong leads Joule's intellectual property development, strategy and implementation. Prior to Joule, he served as IP Counsel to companies including Emergent Biosolutions, Pliva (Teva) and GlycoFi (Merck), where he counseled senior management on developing IP strategy and portfolios, assessment of third-party rights and Hatch-Waxman litigation as well as due diligence, licensing and contract matters. Mr. Hong received a JD/LLM in Intellectual Property from Franklin Pierce Law Center and a BS in Biochemistry & Molecular Biology and Music from Dickinson College.
|Kevin Madden Vice President, Biology Operations|
Dr. Madden is a 13-year veteran of the biotechnology industry, with expertise in the production of renewable fuels and pharmaceutical products. He was previously Chief Scientific Officer at Microbia, Inc. (now a subsidiary of Royal DSM), where he led the company's innovation from the R&D stages through the commercialization of numerous products. He also developed and managed 14 partnerships across multiple markets, and was instrumental in building and managing the company's intellectual property portfolio. Prior to Microbia, Dr. Madden was a Postdoctoral Fellow at Millennium Pharmaceuticals. His research has received several acknowledgments, including a Howard Hughes Medical Institute Predoctoral Fellowship. He holds a BA in Biology from the University of Pennsylvania and PhD in Biology from Yale University.
Joule Partners with Audi to Accelerate Development and Commercialization of Sustainable, Carbon-Neutral Fuels